VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study

Annals of Oncology

Volumn 15, Issue 1, 2004, Pages 123-128

  Levis, A ^a   Anselmo, A P ^b   Ambrosetti, A ^c   Adamo, F ^d   Bertini, M ^e   Cavalieri, E ^b   Gavarotti, P ^f   Genua, A ^g   Liberati, M ^g   Pavone, V ^h   Pietrasanta, D ^a   Ricetti, M M ^c   Scalabrini, D R ⁱ   Salvi, F ^a   Vitolo, U ^e   Angelucci, E ^d   Boccadoro, M ^f   Gallo, E ^e   Mandelli, F ^b  

^a C Arrigo Children's Hospital   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Ospedale Oncologico A Businco   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF PERUGIA   (Italy)

^h UNIVERSITY OF BARI   (Italy)

ⁱ Institute of Research Against Cancer   (Italy)

Author keywords

Chemotherapy; Co morbidity; Elderly; Hodgkin's lymphoma; Prognosis

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; HODGKIN DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 9144251571     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh012     Document Type: Article

References (31)

1. Peterson BA, Pajak TF, Cooper MR et al. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 1982; 66: 889-898.
2. Wedelin C, Bjorkholm M, Biberfeld P et al. Prognostic factors in Hodgkin's disease with special reference to age. Cancer 1984; 53: 1202-1208.
3. Eghbali H, Hoerni-Simon G, De Mascarelle I et al. Hodgkin's disease in the elderly. A series of 30 patients aged older than 70 years. Cancer 1984; 53: 2191-2193.
4. Specht L, Nissen N. Hodgkin's disease and age. Eur J Haematol 1989; 43: 127-135.
5. Bosi A, Ponticelli P, Casini C et al. Clinical data and therapeutic approach in elderly patients with Hodgkin's disease. Haematologica 1989; 74: 463-473.
6. Diaz-Pavon JR, Cabanillas F, Majlis A et al. Outcome of Hodgkin's disease in elderly patients. Hemat Oncol 1995; 13: 19-27.
7. Enblad G, Glimelius B, Sundstrom C. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population based study. Ann Oncol 1991; 2: 297-302.
8. Guinee VF, Giacco GG, Durand M et al. The prognosis of Hodgkin's disease in older adults. J Clin Oncol 1991; 9: 947-953.
9. Erdkamp FL, Breed WP, Bosh LJ et al. Hodgkin's disease in the elderly. A registry-based analysis. Cancer 1992; 70: 830-834.
10. Levis A, Depaoli L, Urgesi A et al. Probability of cure in elderly Hodgkin's disease patients. Haematologica 1994; 79: 46-54.
11. Forsyth PD, Bessell EM, Moloney AJ et al. Hodgkin's disease in patients older than 70 years of age: a registry-based analysis. Eur J Cancer 1997; 33: 1638-1642.
12. La Vecchia C, Levi F, Lucchini F et al. Hodgkin's disease moralità in Europe. Br J Cancer 1991; 64: 723-734.
13. Levis A, Depaoli L, Bertini M et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 1996; 81: 450-456.
14. Zinzani PL, Magagnali M, Bendandi M et al. Efficacy of VBM regimen in the treatment of elderly patients with Hodgkin's disease. Haematologica 2000; 85: 729-732.
15. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14: 65-74.
16. Kaplan EL, Meier P. Non-parametric estimation from incomplete information. J Am Stat Assoc 1958; 53: 457-481.
17. Breslow N. Covariance analysis of censored survival data. Biometrics 1974; 30: 89-99.
18. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
19. Osterborg A, Brandberg Y, Molostova V et al. Randomized, double-blind placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies. J Clin Oncol 2002; 20: 2486-2494.
20. Monfardini S. What we know on variables influencing clinical decision-making in elderly cancer patients. Eur J Cancer 1996; 32A: 12-14.
21. Repetto L, Granetto C, Venturino A et al. Prognostic evaluation of the older cancer patients. In Balducci L, Lyman GH and Ershler WB (eds): Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publisher 1998; 287-300.
22. Bernabei R, Venturiero, V, Tarsitani P et al. The comphrehensive geriatric assessment: when, where, how. Crit Rev Oncol Hematol 2000; 33: 45-56.
23. Diehl V, Franklin J, Hasenclever D et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective than COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16: 3810-3821.
24. Carde P, Cavalli F, Diehl V, Franklin J. Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease? Hemat J 2000; 1: 282-290.
25. Engel C, Loeffler M, Schmitz S et al. Acute hematological toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. Ann Oncol 2000; 11: 1105-1114.
26. Sieber M, Franklin J, Wolf J et al. Acute toxicity limits the feasibility dose and effectiveness of BEACOPP chemotherapy in advanced stage Hodgkin's disease patients older than 65 years. Blood 1999; 94: 2365 (Abstr).
27. Weeks CD, Vose JM, Linch JC et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 2002; 20: 1087-1093.
28. Monfardini S, Ferrucci L, Fratino L et al. Validation of a mutidimensional evaluation scale for use in elderly cancer patients. Cancer 1995; 77: 395-401.
29. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36: 453-471.
30. Extermann M, Overcash J, Lyman JH et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
31. Extermann M, Chen H, Cantor AB et al. Predictors of tolerance to chemotherapy in older cancer patients. A prospective pilot study. Eur J Cancer 2002; 38: 1466-1473.